The Efficacy of Combined Therapy of Regorafenib with Detoxicating and Stasis Softening Chinese Herbal Spleen Tonics in Mid-/Late-Stage Hepatocellular Carcinoma
Table 3
PFS, TTP, and OS of REG and REG-DSS group patients.
Group
TTP (95% CI)
PFS (95% CI)
OS (95% CI)
REG
6.8 (3.5–9.7)
6.8 (3.5–9.7)
17.2 (11.5–22.8)
Treatment ≥4.2 m
7.1 (5.8–8.6)
7.1 (5.8–8.6)
Treatment <4.2 m
3.7 (2.5–4.8)
3.7 (2.5–4.8)
REG-DSS
7.3 (4.2–9.9)
7.3 (4.2–9.9)
18.2 (12.6–23.4)
Treatment ≥4.2 m
7.9 (6.8–8.9)
7.9 (6.8–8.9)
Treatment <4.2 m
4.6 (3.2–6.2)
4.6 (3.2–6.2)
Overall
7.1 (3.9–9.8)
7.1 (3.9–9.8)
17.6 (11.5–22.8)
Treatment ≥4.2 m
7.6 (6.6–8.5)
7.6 (6.6–8.5)
Treatment <4.2 m
4.3 (2.0–6.5)
4.3 (2.0–6.5)
DSS-spleen tonics had synergistic antitumor efficacy with Regorafenib in HCCLM3 cell line.